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COL4AS splice site mutation and aS(IV) collagen mRNA in Alport
syndrome. Mutations affecting the COL4A5 gene encoding the cx5 chain
of type IV collagen, are involved in the pathogenesis of X-linked Alport
syndrome. We used denaturing gradient gel electrophoresis (DGGE) to
screen PCR amplified exons of COL4A5 for point mutations in a set of
18 Alport patients previously characterized by Southern blotting. One
sequence variant was identified in the exon 38 region of a male Alport
patient. Sequence analysis revealed a G to C transversion in the 5'
intron splice donor site downstream from exon 38 (GT to CT). To
determine the effect of the mutation on mRNA splicing, a5(IV) cDNA
was generated from total RNA of peripheral blood lymphocytes.
Subsequent eDNA PCR yielded a product 81 base pairs shorter in the
affected Alport patient, compared to normal controls. The absence of
exon 38 from the a5(IV) cDNA was confirmed by sequence analysis.
The results demonstrated that the mutation leads to skipping of exon 38
in the processing of a5(IV) pre-mRNA. The shortened transcript lacked
27 codons encoding a Gly-X-Y-repeat sequence with a preserved
reading frame, enabling the translation of codons further downstream.
Clinically, the patient presented with juvenile onset Alport syndrome,
end-stage renal failure, and deafness. He had no ocular lesions. Typical
ultrastructural changes of the glomerular basement membrane (GBM)
were shown on electron microscopy. The patient developed anti-GBM
antibodies after renal transplantation, however, renal function deterio-
rated only moderately.
Alport syndrome is characterized by familial renal failure in
association with hematuria and varying degrees of proteinuria,
sensorineural hearing loss, and ocular lesions [1]. It accounts
for about 2% of patients requiring renal replacement therapy
[2]. In the majority of cases, the disease is X-chromosome
linked [3]. Ultrastructural and immunological studies of glomer-
ular basement membrane (GBM) in Alport syndrome supplied
evidence for the involvement of type IV collagen, the main
structural component of the GBM, in the pathogenesis of the
disease [4—7]. Recently, cDNA clones for a novel type IV
collagen a chain, a5(IV), have been isolated [8—10]. The cone-
sponding COL4A5 gene was shown to be located on chromo-
some Xq22 [8], a locus that was previously identified as the
Alport locus in genetic linkage studies [11—15]. Subsequently,
three COL4A5 mutations were detected in Alport patients [16].
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Moreover, in large families COL4A5 mutations could be shown
to segregate in concordance with the Alport phenotype [14—16].
Recently, the exon-intron pattern of the 3' half of the COL4A5
gene has been reported [17] and the gene has been shown to
contain 51 exons [18].
These observations prompted an intense search for COL4A5
mutations in Alport kindreds [reviewed in 19]. Depending on
the methods used, several deletions and other major gene
rearrangements as well as point mutations in translated se-
quences have been identified [20—31]. Deletions have been
observed in only lOto 20% of Alport patients [16, 20, 23, 25, 27,
28], Thus, in most cases small deletions/insertions or point
mutations of COL4A5 may be responsible for Alport syndrome.
In an initial effort to detect COL4A5 point mutations, we
screened 18 Alport patients previously described [28] by using
PCR amplification of exons and their adjacent intron regions in
the 3' end of COL4A5 and subsequently searched for sequence
variants by denaturing gradient gel electrophoresis (DGGE). A
mutation affecting the splice site of intron 38 was identified.
Alternative splicing caused by this mutation was demonstrated
from analysis of a5(IV) cDNA. The eDNA was generated from
peripheral blood lymphocytes mRNA by reverse transcription
and subsequent amplification in a nested PCR reaction. As with
other genetic diseases, such as Duchenne muscular dystrophy,
this method seems to offer a promising new approach for the
analysis of gene defects in Alport syndrome.
Methods
Patients
Patients from 20 unrelated families were originally included in
the study. The clinical data of these patients, and the detection
and characterization of two deletions of the COL4A5 gene by
Southern blotting and PCR amplification of individual exons
were reported previously [28]. In the remaining 18 patients, no
mutations of the COL4A5 gene were detectable by using this
method. These patients were subsequently included into this
study.
The clinical history of the 22-year-old male patient (A-9l30)
reported below, was as follows. The grandparents did not suffer
from renal disease or deafness. However, the patient's mother
had hematuria with end-stage renal disease at the age of 37
years. She died at 45 years from fulminant viral hepatitis. At
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nine years of age, the patient developed sensorineural hearing
loss, confirmed by audiometry. Subsequently, hematuria and
proteinuria were noticed. Renal biopsy revealed typical ultra-
structural changes of the GBM such as thickening and splitting,
which confirmed the diagnosis of Alport syndrome. Ocular
examination revealed no anterior lenticonus nor retinal flecks;
platelet counts were within the normal range. End-stage renal
failure developed at 18 years and chronic intermittent hemodi-
alysis (CIHD) was started. One year later, the patient received
a renal allograft. Two months thereafter, immunosuppressive
therapy was discontinued because of severe pneumonia. Sub-
sequently, the graft was rejected and removed. At the age of 20
years, the patient received a second renal allograft. Low titers
of anti-GBM antibodies were detected two months after trans-
plantation. However, graft function deteriorated only moder-
ately, and then stabilized at lower level (serum creatinine 180 to
200 mol/liter) during a follow-up for more than two years until
the present. Since no serum from this period has been available
until now, the specificity of these antibodies remains to be
established.
DNA analysis
Southern analysis. DNA analysis by Southern blotting was
performed as described previously [28]. Briefly, genomic DNA
was extracted from peripheral blood leukocytes, digested over-
night with EcoRI, PstI, and Taqi restriction enzymes, and was
then separated by electrophoresis on horizontal agarose gels
(0.8%). Separated DNA fragments were subsequently trans-
ferred to uncharged nylon membranes (GeneScreen; DuPont,
Frankfurt, Germany) by Southern blotting and hybridized with
32P-dCTP labeled cDNA probes (JZ4, HT14, PL31, MD6,
PC4b).
PCR. Genomic DNA was extracted from peripheral blood
leukocytes according to the method described by Kunkel et al
[32]. Extracted DNA was adjusted to 50 ng/pi and used as
template in PCR amplification of exon 38 regions of COL4A5.
The primers used for amplification of exon 38 region were: (i)
5'-GTAAGTTFGAATFGTAGC (38A) for the sequence up-
stream of exon 38, and (ii) 5'-TCATGTTCAGCTGTGAA (38B)
for the sequence downstream of the exon (Zhou et al, unpub-
lished results). The 242 bp product generated with these primers
comprised 71 bp of upstream and 90 bp of downstream intron
sequence in addition to the coding sequence of exon 38.
Amplification was performed with 100 ng of genomic DNA
template, 0.5 ftM each primer, 200 M each dNTP, and 2 units
Taq polymerase (Perkin Elmer Cetus, Munich, Germany) under
standard buffer conditions [10 mrvi Tris-HC1, pH 8.3, 50 mM
KCI, 1.5 mrvt MgC12, 0.01% (wt/vol) gelatin]. Forty cycles of
94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 60
seconds were performed.
Denaturing gradient gel electrophoresis (DGGE). Approxi-
mately 70 ng of PCR products from patients and from normal
controls were combined to form heteroduplexes [33]. Incuba-
tion was at 55°C for two hours after denaturing at 98°C for 10
minutes. DGGE was performed under conditions determined
by computer analysis of the exon 38 PCR product by using the
MELT87 program (provided by L. Lerman, Massachusetts
Institute of Technology, Cambridge, Massachusetts, USA).
The program yielded the theoretical melting temperature of the
melting domains of a given DNA molecule [34] to aid the design
of the appropriate denaturant gradient in a 6.8% polyacrylamide
gel. Electrophoresis of exon 38 PCR products was performed
for five hours at 75 V in 10 to 40% linear gradient of denaturants
(100% being equivalent to 40% formamide and 7 M urea). DNA
fragments were visualized after staining with ethidium bromide.
PCR products showing abnormal migrating patterns were di-
rectly sequenced using PCR in combination with the dideoxy
chain termination method (see below).
Reverse transcription and PCR. For RNA preparation, lym-
phocytes from the affected patient A-9130 were separated from
15 ml of whole blood by Ficoll-gradient centrifugation (Phar-
macia, Freiburg, Germany). The cells were cultured for three
days in RPMI 1640 supplemented with 5% fetal call serum,
glutamine and penicillin/streptomycin in standard concentra-
tions. They were stimulated with 10 sg/ml phorbol myristate
acetate (PMA) and 5 nglml ionomycin for 72 hours (Sigma,
Munich, Germany). RNA was extracted from the cells by a
modification of the method described by Chomczynski and
Sacchi [35] by using RNAzoIT° (WAK-Cheniie, Bad Homburg,
Germany). Five micrograms samples of total RNA were reverse
transcribed at 42°C for 50 minutes in 20 d reaction mixtures
containing 50 ng random hexamers as primers, 0.5 m each
dNTP, and 200 U of a genetically engineered reverse tran-
scriptase without RNase H activity (Gibco BRL, Eggenstein,
Germany). Synthesis buffer conditions were 20 m Tris-HCI
pH 8.4, 50 mr's KCI, 2.5 mr's MgCl2, 0.1 mglml BSA. After
termination of transcription by incubating for five minutes at
90°C, template RNA was digested with 2 U RNase H for 20
minutes at 37°C.
Nested PCR [36] was performed in the same reaction tube.
Eight microliters of lOX synthesis buffer, 50 pmol of primer
cD3A and cD3B, respectively, 2.5 U Taq polymerase, and
distilled water were added to the reaction mixture to give a final
volume of 100 jsl. Thirty cycles of PCR (94°C for 30 seconds,
55°C for 30 seconds, and 72°C for 1 minute) were performed on
the sample followed by an incubation at 72°C for five minutes.
Samples (5 d) of the product were added to a 50 .d mixture
containing 5 .d lOX standard PCR buffer (see above), 0.5 LM
primer cD3C and cD3D, respectively, 200 LM each dNTP, and
2 U Taq polymerase. PCR was repeated as above with an
annealing temperature of 50°C. Aliquots (5 d) of the final PCR
product were analyzed by agarose gel electrophoresis.
Primer sequences (nomenclature: cDXA/B = outer set, 5'
and 3', respectively; cDXC/D = inner set, 5' and 3', respec-
tively) were derived from the sequences of COL4A5 exon 36 (5'
primers), and exon 47 (3' primers). The sequences were accord-
ing to Zhou et al [17], with exons 36 and 47 corresponding to
exons 16 and 5, respectively, in the paper. Primer sequences
were: (i) 5'-CCAGGATFACCTGGACAGAA (cD3A); (ii) 5'-
GTGTAATAAGAAATCCATGT (cD3B); (iii) 5'-AGGCGA-
CAAAGGTGATCCTG (cD3C); (iv) 5'-GCAACAGAGGAG-
G11'CCAGG (cD3D).
Nucleotide sequencing. For direct sequencing, PCR products
were purified from agarose gels by using glassmilk (Diagen,
Heidelberg, Germany). After end-labeling of the primers with
[gamma-32P]ATP in a T4 polynucleotide kinase reaction, 30
cycles of strand specific PCR were performed on the purified
products. Primers used for sequencing of the coding strands
were 38A and cD3C, respectively. The noncoding strands were
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Fig. 1. Melt map of the exon 38 region PCR product as determined by
computer analysis. The X-axis indicates base pairs of the PCR product
for the exon 38 region aligned below. The Y-axis indicates the melting
temperature for different regions of the PCR product.
sequenced using primer 38 B and cD3D, respectively. A de-
tailed description of the procedure is given elsewhere [37].
Samples (3 to 5 1.d) of the sequencing reactions were analyzed
by polyacrylamide gel electrophoresis (PAGE). Gels (0.2 mm)
contained 8% polyacrylamide, and 7 54 urea as denaturant.
After fixation in 10% acetic acid, the gels were dryed. Autora-
diography was for 24 hours without intensifying screen.
Results
Identification of single base mutation
Since Southern analysis did not reveal the presence of
mutations in the DNA from 18 of our 20 Alport patients [28], we
decided to systematically search for point mutations by using
DGGE in individual exons and their adjacent introns. Prior to
experimental DGGE analysis, the melting properties of
COL4AS exon 38 were analyzed with a computer algorithm.
For example, the resulting melt map of the exon 38 region PCR
product is shown in Figure 1. Only the melting domains with the
lowest melting temperature at the 5' and 3' ends of the molecule
were accessible to DGGE analysis. The peak temperature
domain within the exon sequence functioned as a natural clamp
preventing complete strand dissociation under the chosen ex-
perimental conditions [331. Thus, the adjacent intron sequences
and the exon-intron boundaries were investigated for muta-
tions. Exon 38 region PCR products derived from genomic
DNA of 18 unrelated Alport patients were analyzed. In one
case, heteroduplex formation indicated the presence of a mu-
tation or polymorphism located in the melting domain, either at
the 5' end or the 3' end of the sequence (Fig. 2).
After purification, exon 38 region PCR product of this indi-
vidual was further characterized by direct sequencing (Fig. 3).
The mutation was shown to affect the 5' splice donor site of
intron 38, changing AGIGT consensus sequence to AGICT ("I"
denotes the exon-intron boundary), thereby creating an Alul
restriction site. No codon was changed by the G to C transver-
sion.
Effect on mRNA splicing
To analyze the potential effect of this mutation on mRNA
splicing, a cDNA-PCR method was used to isolate a5(IV)
mRNA from peripheral blood lymphocytes. After short-term
culturing and stimulation with PMAlionomycin, total RNA was
extracted and reverse transcribed using random hexamers. PCR
with nested primers was used to amplify an 1191 bp segment of
the a5(IV) cDNA corresponding to a sequence encoded by
COL4A5 exons 36 to 47 (Fig. 4A). The specificity of the
cDNA-PCR reaction was confirmed by negative results ob-
tained when reverse transcriptase was omitted from the reac-
tion mixture (Fig. 4B, lane 1). The PCR product gained from the
affected Alport individual showed a decreased length of approx-
imately 80 bp, compared to normal length (Fig. 4B, lanes 2 and
3).
Direct sequencing of both strands of cDNA-PCR products
revealed nucleotides corresponding to exons 37, 38, and 39 to
be present in the control cDNA (Fig. 5). In contrast, a sequence
corresponding to exon 38 was absent from the a5(IV) cDNA of
the affected individual. Consequently, the sequences for exons
37 and 39 were directly joined in the mRNA (Fig. 5), indicating
skipping of exon 38 in the processing of the affected a5(IV)
mRNA. In the resulting cDNA, 81 bp corresponding to 27
amino acid residues from the helical part of the aS(IV) protein
chain were absent. However, the reading frame was conserved,
which would allow translation to continue to the 3' end of the
mRNA.
Discussion
We used DGGE to analyze PCR amplified exons of the
COL4A5 gene in 18 patients with Alport syndrome [28, 38—401.
DGGE was applied without modifying the melting profile of the
DNA fragments by the addition of GC-clamps [33, 39]. There-
fore, the regions accessible to analysis were mainly exon-intron
boundaries, which were present in the first melting domains.
Among several exons analyzed, only exon 38 of one patient
showed a variant melting behavior, indicating the presence of a
variant sequence. This variation could be either a disease
causing mutation or a neutral polymorphism. Further charac-
terization by direct sequencing revealed a G to C transversion,
The mutation affected the highly conserved GT dinucleotide of
the 5' intron splice donor site of intron 38, changing it to GC.
Comparable mutations with changes in the GT dinucleotides
cause complete loss of normal splicing. In Tay-Sachs disease, a
G to C transversion affecting the splice junction of exon 12 of
the HEXA gene leads to the persistence of an unspliced intron
in the hexosaminidase A mRNA [41—43]. However, the inacti-
vation of a normal splice junction may also elicit the use of a
cryptic splice site. To investigate the effect of the splice site
mutation in our patient, the a5(IV) mRNA structure was
analyzed. The difficulty in obtaining a5(IV) mRNA which is
specifically expressed in renal tissue, was circumvented by
using a cDNA-PCR method to amplify illegitimate COL4A5
transcripts from peripheral blood lymphocytes. Illegitimate
transcripts both of normal and abnormal genes have been
shown to be bona fide versions of normal tissue specific
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Fig. 2. DGGE analysis of exon 38 region PCR products. The PCR products were separated in a 10—40% denaturing gel for 5 hr at 75 V. Lane 1,
control DNA; lanes 2—Il, DNA derived from 10 Alport patients, combined with normal control DNA to form heteroduplex DNA. In lane 5,
heteroduplex bands confirm the presence of an altered nucleotide sequence in patient A-9130.
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Fig. 3. Coding strand sequence analysis of the 3' boundary of exon 38 and intron 38. The DNA was PCR-amplified from genomic DNA of a
healthy control and of patient A-9l30. The PCR products were subjected to direct sequencing. Bold letters denote the splice site; AG, the last two
nucleotides of the exon sequence; GT and CT, respectively, the first two nucleotides of the intron sequence. The 0 to C transversion is indicated
by arrows.
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Fig. 4. Generation of ai(IV) cDNA from reversely transcribed
lymphocyte RNA with PCR by using nested primers. (A) Schematic
of a5(IV) cDNA. The triple-helical and the NCI coding regions are
indicated by dark gray and light gray pattern, respectively. Exon
numbers are given above the cDNA. The relative position of the cD3
primers and the extension of the resulting PCR product is shown
below. (B) Agarose gel with the separated cDNA-PCR products
(cD3C/D). Lane 1, negative control; lane 2, normal product; lane 3,
cDNA from patient A-9130; M, marker.
mRNAs [44, 45]. With respect to future diagnostic practicabil-
ity, we decided to extract the RNA from untransformed lym-
phocytes in order to avoid the lengthy transformation proce-
dure. Possible contamination inherent in the cDNA-PCR
procedure was excluded by using a control reaction mixture
from which the reverse transcriptase was omitted. Sequence
analysis of the cDNA-PCR product of the affected patient
confirmed that in the processing of the a5(IV) mRNA exon 38
was skipped. Exon 37 and exon 39 were directly joined with
preservation of the reading frame. Comparable mutations at the
GT dinucleotide of 5' intron splice sites have also been shown
by others to result in skipping of the adjacent exon [46—52]. The
use of a cryptic splice site could not be elucidated since no other
cDNA species were detected. However, we cannot exclude
that a small fraction of alternatively spliced cDNA may have
escaped detection.
The defect at the protein level as deduced from the nucleic
acid data would result in the loss of 27 amino acid residues,
TPGPPGPKGISGPPGNPGLPGEPGPVG, from the central
part of the collagenous Gly-X-Y-repeat sequence between
interruptions 19 and 20 of the a5(IV) chain [10]. This structural
defect may influence both the association of a chain monomers
into trimers, as well as cross linking between different triple-
helical molecules. For example, (i) it is known that interrup-
tions in the collagenous Gly-X-Y sequence, which provide
flexibility to the type IV collagen molecule, match in their
location between different a chains [8—10, 53—55]. A decreased
distance between two such imperfections due to the lack of 27
residues in one a chain may possibly disrupt the normal
structure and flexibility of a heterotrimeric molecule and render
the molecule susceptible to degradation. (ii) The lack of the
lysine residue could influence the side-to-side chain connection
and may possibly decrease the stability of the a5(IV) containing
heterotrimers. (iii) In the network of the basement membrane,
two tnmeric type IV collagen molecules associate in a head-to-
head fashion at the COOH terminus, and four molecules
associate at the NH2 terminus [reviewed in 54—56]. Provided a
correct association at the COOH terminus, a trimer containing
a shortened a chain may only incorrectly associate at the NH2
terminus, thereby disrupting the network formation. However,
more insight into the function of the different a chains in the
supramolecular network of type IV collagen is necessary to
determine the precise molecular mechanism of its disruption in
Alport syndrome.
In conclusion, our study demonstrates the presence of a
COL4A5 splice site mutation in a patient with Alport syndrome.
The phenomenon of illegitimate transcription allowed access to
mRNA which is normally tissue specific. It is likely that the
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Fig. S. Analysis of the cDNA-PCR products. Direct sequencing (coding strand) of the cDNA-PCR products generated from normal control, and
patient A-9130 RNA extracts. Direct junction of exons 37 and 39 is demonstrated in the patient.
cDNA-PCR technique may be useful for the future routine
diagnosis of genetic changes in Alport syndrome.
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